SWOG clinical trial number
S1826

A Phase III, Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vedotin (Adcetris) Plus AVD in Patients (Age >/= 12 years) with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma

Open
Phase
Accrual
17%
Abbreviated Title
Phase III Study of AVD plus nivolumab or BV in pts >/= 12 years in newly diagnosed, advanced cHL
Status Notes
Activation - Effective 7/19/19
Activated
07/19/2019
Participants
ALL NATIONAL CLINICAL TRIALS NETWORK MEMBERS LISTED ON TITLE PAGE

Research committees

Lymphoma

Treatment

Doxorubicin Filgrastim Vinblastine Sulfate Pegfilgrastim Nivolumab Brentuximab Vedotin Dacarbazine RT

Eligibility Criteria Expand/Collapse

See Section 5.0 of the S1826 protocol posted on www.ctsu.org

Publication Information Expand/Collapse

2020

An Intergroup Collaboration for Advanced Stage Classical Hodgkin Lymphoma (cHL) in Adolescents and Young Adults (AYA): SWOG S1826

S Castellino;M LeBlanc;A Herrera;S Parsons;S Punnett;D Hodgson;S Rutherford;N Kahn;L Constine;K Davidson;A Prica;JW Friedberg;K Kelly J Clin Oncol 38: 2020 (suppl; abstr TPS8067); American Society of Clinical Oncology 2020 Annual Meeting, TIPS poster

Reports & Approvals

Trial Locations